Rapport Therapeutics Ended The Quarter With $336.1M In Cash, Cash Equivalents, And Short-term Investments, Excluding Restricted Cash, Which Is Expected To Fund Operations Through The End Of 2026
Rapport Therapeutics Ended The Quarter With $336.1M In Cash, Cash Equivalents, And Short-term Investments, Excluding Restricted Cash, Which Is Expected To Fund Operations Through The End Of 2026
Rapport Therapeutics在季末持有現金、現金等價物和短期投資共3.361億美元，不包括受限制現金，預計可維持運營至2026年底。
Rapport Therapeutics Ended The Quarter With $336.1M In Cash, Cash Equivalents, And Short-term Investments, Excluding Restricted Cash, Which Is Expected To Fund Operations Through The End Of 2026
Rapport Therapeutics在季末持有現金、現金等價物和短期投資共3.361億美元，不包括受限制現金，預計可維持運營至2026年底。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。